» Articles » PMID: 27756910

Validation of the Mutant Selection Window Hypothesis with Fosfomycin Against Escherichia Coli and Pseudomonas Aeruginosa: an in Vitro and in Vivo Comparative Study

Overview
Date 2016 Oct 21
PMID 27756910
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this study was to validate the mutant selection window (MSW) hypothesis in vitro and in vivo with Escherichia coli and Pseudomonas aeruginosa exposed to fosfomycin. Two standard strains of Gram-negative bacteria, those are E. coli ATCC 25922 and P. aeruginosa ATCC 27853, were exposed to fosfomycin at concentrations below MIC, between the MIC and the mutant prevention concentration (MPC), and above the MPC in Luria-Bertani broth and in a tissue-cage infection model, respectively. With the in vitro time-kill studies, there were bacterial re-growth and emergence of resistance thereafter for both strains at antibiotic concentrations of × 4, × 8 and × 16 MIC. In our animal model, the loss in susceptibility of P. aeruginosa at fosfomycin concentrations fluctuated between the lower and upper boundaries of the MSW. In contrast, the emergence of resistant mutants of E. coli was not observed in vivo, regardless of fosfomycin dosage. Interestingly, the in vitro-isolated resistant mutants of E. coli showed a decreased growth rate compared with the susceptible parental strains, whereas no fitness cost in P. aeruginosa was observed. The emergence of antibiotic resistance is shaped by several factors. MSW theory may not apply to all antimicrobial-pathogen combinations. Before it can be used as a framework for the design of antimicrobial therapy, the existence of the window must be demonstrated not only in vitro but also in vivo.

Citing Articles

In Vitro Resistance-Predicting Studies and In Vitro Resistance-Related Parameters-A Hit-to-Lead Perspective.

Krajewska J, Tyski S, Laudy A Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204172 PMC: 11357384. DOI: 10.3390/ph17081068.


In Vitro Antibacterial Activities of Fosfomycin against Isolates from Canine Urinary Tract Infection.

Jariyapamornkoon N, Nuanualsuwan S, Suanpairintr N Animals (Basel). 2024; 14(13).

PMID: 38998027 PMC: 11240368. DOI: 10.3390/ani14131916.


Halicin: A New Horizon in Antibacterial Therapy against Veterinary Pathogens.

Wang S, Zhao K, Chen Z, Liu D, Tang S, Sun C Antibiotics (Basel). 2024; 13(6).

PMID: 38927159 PMC: 11200678. DOI: 10.3390/antibiotics13060492.


Diverse mutant selection windows shape spatial heterogeneity in evolving populations.

King E, Tadele D, Pierce B, Hinczewski M, Scott J PLoS Comput Biol. 2024; 20(2):e1011878.

PMID: 38386690 PMC: 10914271. DOI: 10.1371/journal.pcbi.1011878.


Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the Determination of the Antimicrobial Potency of Compounds.

Krajewska J, Tyski S, Laudy A Antimicrob Agents Chemother. 2023; 67(5):e0137322.

PMID: 37022162 PMC: 10190592. DOI: 10.1128/aac.01373-22.


References
1.
Liu L, Zhu Y, Hu L, Cheng J, Ye Y, Li J . Comparative study of the mutant prevention concentrations of vancomycin alone and in combination with levofloxacin, rifampicin and fosfomycin against methicillin-resistant Staphylococcus epidermidis. J Antibiot (Tokyo). 2013; 66(12):709-12. DOI: 10.1038/ja.2013.87. View

2.
Karageorgopoulos D, Wang R, Yu X, Falagas M . Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2011; 67(2):255-68. DOI: 10.1093/jac/dkr466. View

3.
Li X, Wang L, Zhang X, Yang Y, Gong W, Xu B . Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model. Antimicrob Agents Chemother. 2014; 58(11):6773-81. PMC: 4249358. DOI: 10.1128/AAC.03505-14. View

4.
Rodriguez-Bano J, Alcala J, Cisneros J, Grill F, Oliver A, Horcajada J . Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008; 168(17):1897-902. DOI: 10.1001/archinte.168.17.1897. View

5.
Zhao X, Drlica K . Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis. 2002; 185(4):561-5. DOI: 10.1086/338571. View